Craig-Hallum Downgrades LiveRamp to Hold with $38.50 Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
Craig-Hallum downgraded LiveRamp to Hold from Buy with a $38.50 price target after Publicis said it will acquire LiveRamp for $2.167B in an all-cash transaction, based on an acquisition price of $38.50 per share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RAMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RAMP
Wall Street analysts forecast RAMP stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 37.610
Low
31.00
Averages
40.33
High
53.00
Current: 37.610
Low
31.00
Averages
40.33
High
53.00
About RAMP
LiveRamp Holdings, Inc. is a data collaboration technology company. The Company’s data collaboration network seamlessly unites data across advertisers, platforms, publishers, data providers, and commerce media networks. It offers flexibility to collaborate wherever data lives to support a range of data collaboration use cases. The LiveRamp Data Collaboration Platform enables an organization to unify customer and prospect data (first, second, or third-party) to build a single view of the customer in a way that protects consumer privacy. First-party data is data collected firsthand through a company’s-controlled channels. Second-party data is data that a company shares directly with a business partner. Third-party data is data collected and sold by a company through an online data marketplace to companies with which it does not have a direct relationship. It serves a global customer base from locations in the United States, Europe, and the Asia-Pacific (APAC) region.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Program Launch: LiveRamp has announced the launch of the LiveRamp Agent Builders (LAB) program, aimed at enhancing marketers' capabilities in planning, measurement, and data transformation by introducing more partner-built agents, thereby accelerating marketing efficiency.
- Partner Network Expansion: Founding partners of the LAB program include SemantIQ and Newton Research, which provide AI-driven agent solutions that enable customers to deploy and leverage these tools more quickly on the LiveRamp platform, enhancing the value of data collaboration.
- Positive Market Response: Albertsons Media Collective is already collaborating with Newton Research to utilize the infrastructure of the LAB program, driving the effectiveness of data collaboration and turning cross-media intelligence into actionable insights, further enhancing marketing precision.
- Future Development Direction: LiveRamp will continue to expand the openness of the LAB program, providing opportunities for more marketers and agent builders to adapt quickly and leverage AI-driven marketing tools in an ever-changing market environment.
See More

- Investigation Focus: Halper Sadeh LLC is investigating Caesars Entertainment, Inc. (NASDAQ: CZR) for its sale to Fertitta Entertainment, Inc. at $31.00 per share in cash, potentially violating fiduciary duties and impacting shareholder rights.
- Potential Violations: The sale of XOMA Royalty Corporation (NASDAQ: XOMA) to Ligand Pharmaceuticals Incorporated for $39.00 per share is also under scrutiny, as it may limit superior competing offers, thereby harming shareholder interests.
- Legal Rights: LiveRamp Holdings, Inc. (NYSE: RAMP) is being sold to Publicis Groupe for $38.50 per share, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and options to ensure their interests are protected.
- Shareholder Protection: The transaction involving Taylor Morrison Home Corporation (NYSE: TMHC) selling to Berkshire Hathaway Inc. for $72.50 per common share in cash may lead Halper Sadeh LLC to seek increased compensation and additional disclosures to safeguard shareholder rights.
See More
- Transaction Investigation: Halper Sadeh LLC is investigating the sale of Taylor Morrison Home Corporation to Berkshire Hathaway at $72.50 per share, raising concerns about potential shareholder rights violations and prompting shareholders to consider their legal options.
- Shareholder Rights Protection: The firm is also examining the sale of LiveRamp Holdings, Inc. to Publicis Groupe for $38.50 per share, aiming to ensure shareholders are treated fairly and may seek increased consideration in the transaction.
- Merger Analysis: The merger between Equity Residential and AvalonBay Communities, Inc. will result in Equity Residential shareholders owning approximately 48.8% of the combined entity, with Halper Sadeh LLC potentially advocating for more disclosures and shareholder benefits.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, ensuring no upfront costs for clients, and aims to protect global investors' rights against securities fraud and corporate misconduct.
See More
- Avanos Medical Acquisition Investigation: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in a deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Global Business Travel Group Acquisition: Amex GBT will be acquired by Long Lake Management for $9.50 per share in an all-cash transaction valued at around $6.3 billion, with investigations examining if the board failed to conduct a fair process, potentially impacting shareholder interests.
- Equity Residential Merger Investigation: Equity Residential will merge with AvalonBay Communities, with AvalonBay shareholders receiving 2.793 shares of Equity Residential for each share owned, and investigations are looking into whether the board ensured a fair process, affecting shareholder rights.
- LiveRamp Acquisition Review: LiveRamp is to be acquired by Publicis Groupe for $38.50 per share, totaling an enterprise value of $2.167 billion, with investigations questioning if the board fulfilled fiduciary duties to ensure a fair transaction for shareholders.
See More
- Legal Investigation Launched: Halper Sadeh LLC is investigating LiveRamp Holdings, Inc. (NYSE: RAMP) regarding its sale to Publicis Groupe for $38.50 per share, as there may be violations of shareholder rights that investors need to be aware of.
- Merger Impact Analysis: The merger between NextEra Energy, Inc. (NYSE: NEE) and Dominion Energy, Inc. will result in NextEra shareholders owning approximately 74.5% of the combined entity, prompting shareholders to understand the potential implications for their rights.
- Shareholder Rights Protection: InMed Pharmaceuticals, Inc. (NASDAQ: INM) is merging with Mentari Therapeutics, Inc., which is expected to leave InMed shareholders with only about 1.51% ownership in the combined company, highlighting the need for shareholders to be informed about their legal rights.
- Advocacy for Investor Rights: Halper Sadeh LLC represents investors globally, seeking increased consideration and additional disclosures to support those affected by securities fraud and corporate misconduct, thereby enhancing investor protection efforts.
See More
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the transaction between LiveRamp Holdings, Inc. and Publicis Groupe, where LiveRamp shareholders are expected to receive $38.50 per share in cash, potentially providing significant returns for shareholders.
- Merger Transaction Analysis: In the merger between NextEra Energy, Inc. and Dominion Energy, Inc., NextEra shareholders will own approximately 74.5% of the combined company upon closing, demonstrating strong consolidation capabilities in the energy market.
- Share Exchange Proposal: In the NextEra and Dominion transaction, Dominion shareholders are expected to receive 0.8138 shares of NextEra for each share of Dominion, which may impact the long-term interests of shareholders from both companies.
- Emerging Pharma Merger: The merger between InMed Pharmaceuticals, Inc. and Mentari Therapeutics, Inc. is expected to result in InMed shareholders owning approximately 1.51% of the combined company, reflecting integration trends and market potential in the pharmaceutical sector.
See More








